// App-Quantinova.ai

2110 : Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

Researchers

Presenter

  • Laure Gossec

Principal Investigators

  • Mohamed Sharaf

  • Elke Theander

  • Marlies Neuhold

  • Paul Bergmans

  • May Shawi

  • Michelle Perate

  • Christine Contré

  • Laura Coates

Medical Centers

  • Sorbonne Universites, Paris, France

  • Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates

  • Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden

  • Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland

  • Formerly at Janssen, Breda, Netherlands

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Scientific Affairs, Horsham, PA

  • Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

Locations

  • France

  • United Arab Emirates

  • Sweden

  • Switzerland

  • Netherlands

  • United States

  • United Kingdom

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • guselkumab (IV)

  • Grace

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03796858

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved